At the news
? NEUTRALIMPACT 1/10 COURT-RULING filed Sep 2, 2026 at 20:00 ET
A magistrate judge in the Novo Nordisk patent lawsuit against Mochi Health Corp. issued a procedural order governing in-house counsel access to highly sensitive (AEO) discovery materials. The ruling permits up to two designated in-house counsel per party to access AEO information under specified guardrails, resolving a discovery dispute but not addressing any merits liability or damages. This is a routine discovery administration order with no financial or business impact on Novo Nordisk.
- Order addresses in-house counsel access to AEO (Attorneys' Eyes Only) information in Novo Nordisk's patent litigation against Mochi Health.
- Each party may designate up to two 'Designated House Counsel' with access to AEO, subject to guardrails including a declaration re competitive decision-making.
- The ruling is a discovery dispute resolution, not a merits determination, injunction, or damages award.
- No financial figures, damages, or business restrictions are mentioned in the order.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access